查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1485065

氣喘治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、分產品（吸入器、霧化器）、給藥途徑、地區和競爭細分，2019-2029F

Asthma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Product (Inhalers, Nebulizers), By Route of Administration, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球氣喘治療市場估值為235.2 億美元，預計在預測期內穩定成長，到2029 年複合年成長率為3.25%。並對醫療保健提出挑戰全球各地的系統。隨著其盛行率穩定上升，全球氣喘治療市場一直在迅速發展，以滿足患者和醫療保健提供者的需求。氣喘以氣道發炎和收縮為特徵，表現為喘息、氣短、咳嗽和胸悶等各種症狀。

市場概況
預測期 2025-2029
2023 年市場規模 235.2億美元
2029 年市場規模 283.8億美元
2024-2029 年複合年成長率 3.25%
成長最快的細分市場 聯合療法
最大的市場 北美洲

吸入性皮質類固醇、白三烯調節劑和長效BETA受體激動劑是治療氣喘的常用處方藥物。這些藥物透過針對潛在的發炎和支氣管收縮來幫助緩解症狀並防止病情惡化。此外，沙丁胺醇等短效BETA受體激動劑通常用於在急性氣喘發作期間立即緩解症狀，提供快速支氣管擴張以改善氣流並緩解症狀。全球氣喘治療市場可望進一步發展並改善氣喘管理。藥物開發的創新，包括引入新的生物製劑和其他新療法，有望為嚴重且不受控制的氣喘患者提供額外的治療選擇。尤其是生物製劑，針對氣喘發病機制中涉及的特定途徑，提供適合個別患者需求的個人化治療方法。這些治療方式的進步有可能徹底改變氣喘治療，為患者提供更好的治療效果並改善生活品質。

對氣喘遺傳和分子基礎的持續研究有望推動個人化治療策略並增強我們對該疾病的了解。透過識別與氣喘易感性和嚴重程度相關的遺傳標記和分子途徑，研究人員旨在開發標靶療法，解決導致疾病的潛在機制。基於基因譜和生物標記分析的個人化治療計劃可以使醫療保健提供者能夠根據個別患者的情況量身定做治療方案，最佳化治療結果並最大限度地減少不良反應。為了因應全球日益成長的氣喘負擔，全球氣喘治療市場不斷發展。醫學研究、藥物開發和個人化醫療的進步為氣喘患者帶來了新的希望，提供了一系列治療選擇並改善了整體氣喘管理。透過利用創新療法和個人化治療方法，醫療保健提供者可以更好地滿足氣喘患者的需求，減輕症狀負擔，預防病情加重，並提高生活品質。

主要市場促進因素

哮喘盛行率上升

增加醫療支出

主要市場挑戰

通用競爭

主要市場趨勢

技術進步

細分市場洞察

藥品類別見解

產品洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球氣喘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（抗發炎藥、合併療法、支氣管擴張劑）
    • 依產品（吸入器（乾粉吸入器、定量吸入器、軟霧吸入器）、霧化器）
    • 依給藥途徑（口服、吸入、其他）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖
    • 按藥物類別
    • 按產品分類
    • 依給藥途徑
    • 按地區

第 5 章：亞太地區氣喘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按產品分類
    • 依給藥途徑
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲氣喘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按產品分類
    • 依給藥途徑
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美氣喘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按產品分類
    • 依給藥途徑
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲氣喘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按產品分類
    • 依給藥途徑
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲氣喘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按產品分類
    • 依給藥途徑
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 12 章：全球氣喘治療市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • GSK plc.
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca plc.
  • Boehringer Ingelheim International GmbH
  • Sanofi SA
  • Koninklijke Philips NV
  • Becton, Dickinson and Company
  • Sunovion Pharmaceuticals, Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 22132

Global Asthma Therapeutics Market was valued at USD 23.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 3.25% through 2029. Asthma remains a significant global health concern, affecting millions of individuals worldwide and posing challenges for healthcare systems across the globe. With its prevalence steadily increasing, the global asthma therapeutics market has been evolving rapidly to meet the needs of patients and healthcare providers. Characterized by airway inflammation and constriction, asthma manifests through various symptoms such as wheezing, shortness of breath, coughing, and chest tightness.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 23.52 Billion
Market Size 2029USD 28.38 Billion
CAGR 2024-20293.25%
Fastest Growing SegmentCombination Therapy
Largest MarketNorth America

Inhaled corticosteroids, leukotriene modifiers, and long-acting beta-agonists are among the commonly prescribed medications for asthma management. These medications help alleviate symptoms and prevent exacerbations by targeting underlying inflammation and bronchial constriction. Additionally, short-acting beta-agonists such as albuterol are often used for immediate symptom relief during acute asthma attacks, providing rapid bronchodilation to improve airflow and alleviate symptoms. The global asthma therapeutics market is poised for further evolution and improvement in asthma management. Innovations in drug development, including the introduction of new biologics and other novel therapies, hold promise for providing additional treatment options for patients with severe and uncontrolled asthma. Biologics, in particular, target specific pathways involved in asthma pathogenesis, offering personalized treatment approaches tailored to individual patient needs. These advancements in treatment modalities have the potential to revolutionize asthma management, offering better outcomes and improved quality of life for patients.

Ongoing research into the genetic and molecular basis of asthma is expected to drive personalized treatment strategies and enhance our understanding of the disease. By identifying genetic markers and molecular pathways associated with asthma susceptibility and severity, researchers aim to develop targeted therapies that address the underlying mechanisms driving the disease. Personalized treatment plans based on genetic profiling and biomarker analysis could enable healthcare providers to tailor therapies to individual patient profiles, optimizing treatment outcomes and minimizing adverse effects. The global asthma therapeutics market continues to evolve in response to the growing burden of asthma worldwide. Advances in medical research, drug development, and personalized medicine offer new hope for patients with asthma, providing a range of treatment options and improving overall asthma management. By leveraging innovative therapies and personalized treatment approaches, healthcare providers can better meet the needs of patients with asthma, reducing symptom burden, preventing exacerbations, and improving quality of life.

Key Market Drivers

Rising Prevalence of Asthma

Asthma is a global health concern, affecting people of all ages, from children to the elderly. The burden of asthma is not just limited to its prevalence but extends to its impact on patients' lives and healthcare costs. Several factors contribute to the increasing prevalence of asthma. Exposure to various environmental triggers such as allergens, air pollution, and tobacco smoke can increase the risk of asthma. Urbanization and industrialization have led to increased exposure to these triggers in many parts of the world. A family history of asthma or allergic conditions can predispose individuals to the development of asthma. Genetic factors play a significant role in susceptibility to the disease.

Sedentary lifestyles, changes in dietary habits, and increased stress levels have been linked to the rising prevalence of asthma. These factors can lead to obesity, which is a known risk factor for asthma. Improved diagnostic methods and increased awareness about asthma have led to more individuals seeking medical help, resulting in a higher number of reported cases. As the global population continues to age, the prevalence of chronic diseases like asthma also increases, as the condition is not limited to any specific age group. Developing countries are witnessing a rise in asthma cases due to urbanization and industrial growth, leading to increased exposure to asthma triggers. The increasing prevalence of asthma has driven the growth of the global asthma therapeutics market. Pharmaceutical companies have been investing in research and development to create more effective treatments for asthma. The market includes a wide range of therapeutics, including inhaled corticosteroids, long-acting beta-agonists, leukotriene modifiers, and monoclonal antibodies, among others.

Increasing Healthcare Expenditure

Asthma is a chronic respiratory condition that affects millions of people worldwide. With a rising prevalence of asthma and an increasing focus on healthcare, the global asthma therapeutics market is experiencing significant growth. One of the primary drivers of this growth is the increasing healthcare expenditure in various countries. As governments and healthcare organizations recognize the growing burden of chronic diseases like asthma, they are allocating larger budgets to healthcare. Increased healthcare expenditure is enabling better access to healthcare services, including improved diagnosis and management of asthma. These investments have a direct impact on the asthma therapeutics market, driving its growth. Asthma therapeutics have come a long way in recent years, thanks to advancements in medical research and technology. Pharmaceutical companies are investing heavily in the development of innovative drugs and therapies to improve asthma management. With greater healthcare spending, more resources are available for research and development, leading to the creation of more effective and efficient asthma treatments.

In many countries, the accessibility of asthma medications has improved significantly due to increased healthcare expenditure. This means that patients have better access to a wide range of asthma therapeutics, from quick-relief inhalers to long-term control medications. This improved access ensures that patients can manage their condition effectively, leading to better health outcomes. Higher healthcare spending also allows for increased asthma awareness campaigns and patient education programs. When patients are well-informed about their condition and treatment options, they are more likely to adhere to their treatment plans. This ultimately leads to better control of asthma, reducing the severity and frequency of symptoms and hospital admissions.

Research and development in the asthma therapeutics market are heavily influenced by healthcare expenditure. Greater financial support for research activities results in the discovery of new drugs and therapies that can revolutionize asthma management. These advancements benefit both patients and the pharmaceutical industry, as they create a more competitive and dynamic market. The global asthma therapeutics market is expanding as healthcare expenditure rises. In addition to the core treatment options, there is a growing interest in personalized medicine and biologics in the treatment of asthma. These innovative approaches offer a promising future for patients with severe or difficult-to-treat asthma.

While increasing healthcare expenditure is driving growth in the asthma therapeutics market, there are some challenges to address. Balancing the need for better treatments with the rising cost of healthcare is a delicate task. It's essential to ensure that healthcare resources are utilized efficiently and that affordable treatment options are available to all, regardless of socioeconomic status.

Key Market Challenges

Generic Competition

The patent expirations of several blockbuster asthma drugs have led to increased competition from generic alternatives. While this can drive down prices, it can also pose a challenge for pharmaceutical companies and innovators in terms of sustaining profitability and investing in research and development for new, innovative therapies. Asthma is a heterogeneous disease with various phenotypes and endotypes. Developing therapeutics that cater to the diverse needs of patients is a complex task. Tailoring treatments to individual asthma subtypes is challenging, as it requires a deep understanding of the underlying mechanisms and can be costly. Asthma management relies on long-term adherence to medication regimens. However, many patients struggle with non-adherence, whether due to inconvenience, side effects, or lack of understanding of the importance of consistent treatment. This can hinder the effectiveness of asthma therapeutics and result in uncontrolled asthma.

Key Market Trends

Technological Advancements

Asthma is a chronic respiratory condition that affects millions of people worldwide, causing symptoms such as wheezing, shortness of breath, and coughing. With the increasing prevalence of asthma cases globally, the demand for effective and innovative asthma therapeutics is on the rise. Technological advancements have played a pivotal role in the development of new and improved treatments, leading to a booming Global Asthma Therapeutics Market. Technological innovations have led to more accurate and efficient methods for diagnosing asthma. Traditional diagnostic methods, such as spirometry and peak flow measurements, have been supplemented with advanced diagnostic tools like exhaled nitric oxide (FeNO) testing and fractional exhaled nitric oxide (FeNO) monitors. These tools offer better insights into airway inflammation, aiding in more precise asthma diagnosis. Telemedicine has revolutionized the healthcare industry, providing convenient access to healthcare professionals and specialists. Remote monitoring devices, including smart inhalers and wearable sensors, allow patients and doctors to track asthma symptoms and medication adherence. This real-time data helps in creating personalized treatment plans and ensures better management of the condition.

Advancements in genetic research and personalized medicine have allowed for the development of targeted asthma treatments. By identifying specific genetic markers associated with asthma, pharmaceutical companies can create therapies tailored to an individual's unique genetic profile. This approach leads to more effective treatments and fewer side effects. Biologics, a class of medications derived from living organisms, have emerged as a groundbreaking treatment for severe asthma. These drugs target specific molecules in the immune system, effectively reducing inflammation and preventing asthma exacerbations. Monoclonal antibodies, a type of biologic, are increasingly used to treat severe asthma, offering hope to patients who do not respond well to traditional therapies. Inhalers have come a long way with technological advancements. Smart inhalers, equipped with Bluetooth connectivity and companion mobile apps, help patients track their inhaler usage, monitor medication adherence, and receive reminders for inhalation. These innovations enhance patient engagement and contribute to better asthma management.

AI and machine learning are invaluable tools in asthma research. They analyze vast amounts of patient data, identify patterns, and predict asthma exacerbations. Researchers use AI to develop predictive models that can guide treatment decisions and improve patient outcomes. Advanced computational modeling and virtual screening techniques are accelerating the drug discovery process. These technologies help identify potential asthma therapies faster, reducing the time and costs associated with bringing new medications to market. As a result, the pipeline for asthma drug candidates is growing rapidly.

Segmental Insights

Drug Class Insights

Based on drug class, Combination Therapy emerged as the fastest growing segment in the global market for asthma therapeutics in 2023. Combination therapy can provide better symptom control by addressing multiple aspects of asthma simultaneously. By combining a long-acting beta-agonist (LABA) with an ICS, for instance, patients can experience improved lung function, reduced inflammation, and fewer exacerbations. Asthma is not a one-size-fits-all condition. Combination therapy allows for personalized treatment regimens that can be adjusted to suit an individual's specific needs, considering factors like the severity of their asthma, their response to different medications, and comorbid conditions. Traditional reliance on SABA medications may lead to overuse and increased risk of side effects. Combination therapy can reduce the need for SABA, promoting safer, more effective asthma management. Asthma exacerbations can be severe and sometimes life-threatening. Combination therapy can significantly reduce the risk of exacerbations, leading to better long-term outcomes for asthma patients. With the development of advanced inhaler devices, patients can now conveniently administer combination therapies, making them easier to incorporate into their daily routines.

Product Insights

Based on product, the inhalers is projected to experience rapid growth in the global asthma therapeutics market during the forecast period. Inhalers deliver medication directly to the airways, ensuring that the drugs act where they are needed most. This targeted delivery reduces the risk of systemic side effects and provides faster relief. Inhalers are user-friendly and offer an easy, convenient method of medication administration. This enhances patient compliance, as individuals are more likely to adhere to their prescribed treatment plans. Inhalers typically require lower medication doses compared to oral medications. This can lead to cost savings for patients and healthcare systems and decrease the potential for adverse reactions. Inhalers come in various types, including short-acting and long-acting bronchodilators, inhaled corticosteroids, and combination therapies. This allows healthcare providers to tailor treatment regimens to the individual needs of asthma patients.

Regional Insights

Based on region, North America emerged as the dominant region in the Global Asthma Therapeutics Market in 2023, holding the largest market share in terms of value. One of the primary reasons for North America's leading position in the global asthma therapeutics market is the high prevalence of asthma in the region. The United States, Canada, and Mexico collectively have a substantial population suffering from asthma, which drives the demand for effective asthma treatments and medications. As a result, pharmaceutical companies are heavily invested in the North American market, leading to a robust pipeline of asthma therapeutics. North America boasts a sophisticated healthcare infrastructure, characterized by state-of-the-art medical facilities, a well-trained healthcare workforce, and a strong emphasis on research and development. This conducive environment has allowed the region to excel in asthma research, enabling the development of innovative therapies and treatments. The presence of top-tier research institutions and pharmaceutical companies in North America has further contributed to the region's dominance in the asthma therapeutics market.

Key Market Players

Teva Pharmaceutical Industries Ltd.

GSK plc.

Merck & Co., Inc.

F. Hoffmann-La Roche Ltd.

AstraZeneca plc.

Boehringer Ingelheim International GmbH

Sanofi S.A.

Koninklijke Philips N.V.

Becton, Dickinson and Company

Sunovion Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Asthma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Asthma Therapeutics Market, By Drug Class:

    Anti-inflammatory Combination Therapy Bronchodilators

Asthma Therapeutics Market, By Product:

    Inhalers Nebulizers

Asthma Therapeutics Market, By Route of Administration:

    Oral Inhaled Others

Asthma Therapeutics Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Asthma Therapeutics Market.

Available Customizations:

Global Asthma Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Asthma Therapeutics Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Drug Class (Anti-inflammatory, Combination Therapy, Bronchodilators)
    • 4.2.2. By Product (Inhalers (Dry powder inhalers, Metered dose inhalers, Soft mist inhalers), Nebulizers)
    • 4.2.3. By Route of Administration (Oral, Inhaled, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2023)
  • 4.3. Market Map
    • 4.3.1. By Drug Class
    • 4.3.2. By Product
    • 4.3.3. By Route of Administration
    • 4.3.4. By Region

5. Asia Pacific Asthma Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class
    • 5.2.2. By Product
    • 5.2.3. By Route of Administration
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Asthma Therapeutics Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Drug Class
        • 5.3.1.2.2. By Product
        • 5.3.1.2.3. By Route of Administration
    • 5.3.2. India Asthma Therapeutics Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Drug Class
        • 5.3.2.2.2. By Product
        • 5.3.2.2.3. By Route of Administration
    • 5.3.3. Australia Asthma Therapeutics Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Drug Class
        • 5.3.3.2.2. By Product
        • 5.3.3.2.3. By Route of Administration
    • 5.3.4. Japan Asthma Therapeutics Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Drug Class
        • 5.3.4.2.2. By Product
        • 5.3.4.2.3. By Route of Administration
    • 5.3.5. South Korea Asthma Therapeutics Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Drug Class
        • 5.3.5.2.2. By Product
        • 5.3.5.2.3. By Route of Administration

6. Europe Asthma Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Product
    • 6.2.3. By Route of Administration
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Asthma Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Route of Administration
    • 6.3.2. Germany Asthma Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Route of Administration
    • 6.3.3. Spain Asthma Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Route of Administration
    • 6.3.4. Italy Asthma Therapeutics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Drug Class
        • 6.3.4.2.2. By Product
        • 6.3.4.2.3. By Route of Administration
    • 6.3.5. United Kingdom Asthma Therapeutics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Drug Class
        • 6.3.5.2.2. By Product
        • 6.3.5.2.3. By Route of Administration

7. North America Asthma Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Product
    • 7.2.3. By Route of Administration
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Asthma Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Route of Administration
    • 7.3.2. Mexico Asthma Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Route of Administration
    • 7.3.3. Canada Asthma Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Route of Administration

8. South America Asthma Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Product
    • 8.2.3. By Route of Administration
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Asthma Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Route of Administration
    • 8.3.2. Argentina Asthma Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Route of Administration
    • 8.3.3. Colombia Asthma Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Route of Administration

9. Middle East and Africa Asthma Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Product
    • 9.2.3. By Route of Administration
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Asthma Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Route of Administration
    • 9.3.2. Saudi Arabia Asthma Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Route of Administration
    • 9.3.3. UAE Asthma Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Route of Administration

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Asthma Therapeutics Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Teva Pharmaceutical Industries Ltd.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. GSK plc.
  • 14.3. Merck & Co., Inc.
  • 14.4. F. Hoffmann-La Roche Ltd.
  • 14.5. AstraZeneca plc.
  • 14.6. Boehringer Ingelheim International GmbH
  • 14.7. Sanofi S.A.
  • 14.8. Koninklijke Philips N.V.
  • 14.9. Becton, Dickinson and Company
  • 14.10. Sunovion Pharmaceuticals, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer